Relay Therapeutics, Inc. (RLAY)
NASDAQ: RLAY · IEX Real-Time Price · USD
6.11
-0.10 (-1.61%)
At close: Apr 18, 2024, 4:00 PM
6.17
+0.06 (0.98%)
After-hours: Apr 18, 2024, 7:50 PM EDT

Relay Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 202320222021202020192018
Revenue
25.551.383.0382.6500
Revenue Growth (YoY)
1749.82%-54.41%-96.34%---
Gross Profit
25.551.383.0382.6500
Selling, General & Admin
74.9565.9857.3938.5913.748.86
Research & Development
330.02246.36172.6599.8670.3141.03
Other Operating Expenses
00134.86000
Operating Expenses
404.97312.33364.89138.4584.0549.89
Operating Income
-379.42-310.95-361.86-55.8-84.05-49.89
Other Expense / Income
-37.45-20.442.01-3.38-8.74-1.1
Pretax Income
-341.97-290.51-363.87-52.41-75.31-48.79
Net Income
-341.97-290.51-363.87-52.41-75.31-48.79
Preferred Dividends
000177.7900
Net Income Common
-341.97-290.51-363.87-230.2-75.31-48.79
Shares Outstanding (Basic)
123112954332
Shares Outstanding (Diluted)
123112954332
Shares Change
9.22%17.97%123.22%1135.17%38.84%-
EPS (Basic)
-2.79-2.59-3.82-5.40-21.82-19.63
EPS (Diluted)
-2.79-2.59-3.82-5.40-21.82-19.63
Free Cash Flow
-304.44-238.55-77.88-104.42-74.12-45.82
Free Cash Flow Per Share
-2.48-2.13-0.82-2.45-21.48-18.43
Gross Margin
100.00%100.00%100.00%100.00%--
Operating Margin
-1485.25%-22516.44%-11946.58%-67.51%--
Profit Margin
-1338.66%-21036.13%-12012.94%-278.51%--
Free Cash Flow Margin
-1191.74%-17273.86%-2571.05%-126.33%--
EBITDA
-336.7-286.38-359.95-48.86-72.46-46.63
EBITDA Margin
-1318.03%-20737.07%-11883.36%-59.12%--
Depreciation & Amortization
5.274.133.933.552.852.15
EBIT
-341.97-290.51-363.87-52.41-75.31-48.79
EBIT Margin
-1338.66%-21036.13%-12012.94%-63.41%--
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).